BZPEERPapers, people, evidence and research paths
Menu

Discover

SearchFind papers, people, topics, institutions and opportunities from one place.GraphSee how papers, authors, topics and evidence connect.

Research tools

HomeContinue from the papers, people and topics that matter now.CollectionsTurn saved papers into reading lists, evidence maps and shareable context.ResearchReconstruct the path that led you from search to paper to question.CollaborationMove from a paper, topic or expert request into a focused thread.PublishCreate full-text research articles with metadata, formulas and versions.

Network

ExpertsFind specialists whose work and reviews explain why they can help.CommunitiesJoin research groups organized around papers, topics and shared evidence.

Opportunities

ListingsBrowse roles, calls and collaborations connected to real research context.

Account

Log inReturn to your saved papers, graph views and active threads.Create accountStart saving papers, building a research trail and joining teams.
Log inCreate account

Source author record

Tze Leung Lai

Tze Leung Lai appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record
Methodologymath.STStatistics TheoryApplicationsmath.PRq-fin.PM

Catalog footprint

What is connected

10works
6topics
4close collaborators

Actions

Connect this record

Log in to claim
Open graphBrowse works

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

10 published item(s)

preprint2014arXiv

A New Approach to Designing Phase I-II Cancer Trials for Cytotoxic Chemotherapies

Recently there has been much work on early phase cancer designs that incorporate both toxicity and efficacy data, called Phase I-II designs because they combine elements of both phases. However, they do not explicitly address the Phase II hypothesis test of $H_0: p\le p_0$, where $p$ is the probability of efficacy at the estimated maximum tolerated dose (MTD) $\widehatη$ from Phase I and $p_0$ is the baseline efficacy rate. Standard practice for Phase II remains to treat $p$ as a fixed, unknown parameter and to use Simon's 2-stage design with all patients dosed at $\widehatη$. We propose a Phase I-II design that addresses the uncertainty in the estimate $p=p(\widehatη)$ in $H_0$ by using sequential generalized likelihood theory. Combining this with a Phase I design that incorporates efficacy data, the Phase I-II design provides a common framework that can be used all the way from the first dose of Phase I through the final accept/reject decision about $H_0$ at the end of Phase II, utilizing both toxicity and efficacy data throughout. Efficient group sequential testing is used in Phase II that allows for early stopping to show treatment effect or futility. The proposed Phase I-II design thus removes the artificial barrier between Phase I and Phase II, and fulfills the objectives of searching for the MTD and testing if the treatment has an acceptable response rate to enter into a Phase III trial.

0 citations0 reviewsNo code linkedOpen access
preprint2013arXiv

A general theory of particle filters in hidden Markov models and some applications

By making use of martingale representations, we derive the asymptotic normality of particle filters in hidden Markov models and a relatively simple formula for their asymptotic variances. Although repeated resamplings result in complicated dependence among the sample paths, the asymptotic variance formula and martingale representations lead to consistent estimates of the standard errors of the particle filter estimates of the hidden states.

0 citations0 reviewsNo code linkedOpen access
preprint2012arXiv

A sequential Monte Carlo approach to computing tail probabilities in stochastic models

Sequential Monte Carlo methods which involve sequential importance sampling and resampling are shown to provide a versatile approach to computing probabilities of rare events. By making use of martingale representations of the sequential Monte Carlo estimators, we show how resampling weights can be chosen to yield logarithmically efficient Monte Carlo estimates of large deviation probabilities for multidimensional Markov random walks.

0 citations0 reviewsNo code linkedOpen access
preprint2012arXiv

Evaluating probability forecasts

Probability forecasts of events are routinely used in climate predictions, in forecasting default probabilities on bank loans or in estimating the probability of a patient's positive response to treatment. Scoring rules have long been used to assess the efficacy of the forecast probabilities after observing the occurrence, or nonoccurrence, of the predicted events. We develop herein a statistical theory for scoring rules and propose an alternative approach to the evaluation of probability forecasts. This approach uses loss functions relating the predicted to the actual probabilities of the events and applies martingale theory to exploit the temporal structure between the forecast and the subsequent occurrence or nonoccurrence of the event.

0 citations0 reviewsNo code linkedOpen access
preprint2011arXiv

Efficient adaptive designs with mid-course sample size adjustment in clinical trials

Adaptive designs have been proposed for clinical trials in which the nuisance parameters or alternative of interest are unknown or likely to be misspecified before the trial. Whereas most previous works on adaptive designs and mid-course sample size re-estimation have focused on two-stage or group sequential designs in the normal case, we consider here a new approach that involves at most three stages and is developed in the general framework of multiparameter exponential families. Not only does this approach maintain the prescribed type I error probability, but it also provides a simple but asymptotically efficient sequential test whose finite-sample performance, measured in terms of the expected sample size and power functions, is shown to be comparable to the optimal sequential design, determined by dynamic programming, in the simplified normal mean case with known variance and prespecified alternative, and superior to the existing two-stage designs and also to adaptive group sequential designs when the alternative or nuisance parameters are unknown or misspecified.

0 citations0 reviewsNo code linkedOpen access
preprint2011arXiv

Generalized Likelihood Ratio Statistics and Uncertainty Adjustments in Efficient Adaptive Design of Clinical Trials

A new approach to adaptive design of clinical trials is proposed in a general multiparameter exponential family setting, based on generalized likelihood ratio statistics and optimal sequential testing theory. These designs are easy to implement, maintain the prescribed Type I error probability, and are asymptotically efficient. Practical issues involved in clinical trials allowing mid-course adaptation and the large literature on this subject are discussed, and comparisons between the proposed and existing designs are presented in extensive simulation studies of their finite-sample performance, measured in terms of the expected sample size and power functions.

0 citations0 reviewsNo code linkedOpen access
preprint2011arXiv

Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs

A general framework is proposed for Bayesian model-based designs of Phase I cancer trials, in which a general criterion for coherence (Cheung, 2005) of a design is also developed. This framework can incorporate both "individual" and "collective" ethics into the design of the trial. We propose a new design which minimizes a risk function composed of two terms, with one representing the individual risk of the current dose and the other representing the collective risk. The performance of this design, which is measured in terms of the accuracy of the estimated target dose at the end of the trial, the toxicity and overdose rates, and certain loss functions reflecting the individual and collective ethics, is studied and compared with existing Bayesian model-based designs and is shown to have better performance than existing designs.

0 citations0 reviewsNo code linkedOpen access
preprint2011arXiv

Mean--variance portfolio optimization when means and covariances are unknown

Markowitz's celebrated mean--variance portfolio optimization theory assumes that the means and covariances of the underlying asset returns are known. In practice, they are unknown and have to be estimated from historical data. Plugging the estimates into the efficient frontier that assumes known parameters has led to portfolios that may perform poorly and have counter-intuitive asset allocation weights; this has been referred to as the "Markowitz optimization enigma." After reviewing different approaches in the literature to address these difficulties, we explain the root cause of the enigma and propose a new approach to resolve it. Not only is the new approach shown to provide substantial improvements over previous methods, but it also allows flexible modeling to incorporate dynamic features and fundamental analysis of the training sample of historical data, as illustrated in simulation and empirical studies.

0 citations0 reviewsNo code linkedOpen access
preprint2011arXiv

Multistage tests of multiple hypotheses

Conventional multiple hypothesis tests use step-up, step-down, or closed testing methods to control the overall error rates. We will discuss marrying these methods with adaptive multistage sampling rules and stopping rules to perform efficient multiple hypothesis testing in sequential experimental designs. The result is a multistage step-down procedure that adaptively tests multiple hypotheses while preserving the family-wise error rate, and extends Holm's (1979) step-down procedure to the sequential setting, yielding substantial savings in sample size with small loss in power.

0 citations0 reviewsNo code linkedOpen access
preprint2010arXiv

Approximate Dynamic Programming and Its Applications to the Design of Phase I Cancer Trials

Optimal design of a Phase I cancer trial can be formulated as a stochastic optimization problem. By making use of recent advances in approximate dynamic programming to tackle the problem, we develop an approximation of the Bayesian optimal design. The resulting design is a convex combination of a "treatment" design, such as Babb et al.'s (1998) escalation with overdose control, and a "learning" design, such as Haines et al.'s (2003) $c$-optimal design, thus directly addressing the treatment versus experimentation dilemma inherent in Phase I trials and providing a simple and intuitive design for clinical use. Computational details are given and the proposed design is compared to existing designs in a simulation study. The design can also be readily modified to include a first stage that cautiously escalates doses similarly to traditional nonparametric step-up/down schemes, while validating the Bayesian parametric model for the efficient model-based design in the second stage.

0 citations0 reviewsNo code linkedOpen access